A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

A New Frontier for research: Liftoff for the All of Us study

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

This week, we will witness liftoff for a new National Institutes of Health (NIH) initiative that strives to move our current state of research to a future state of precision medicine where data is broken out of siloes. Researchers will have novel opportunities to study the data, which could speed medical breakthroughs.

I’ve had the privilege of seeing the All of Us Research Program grow from a kernel of an idea into a path-breaking program that ambitiously aims to gather data from 1 million or more diverse people—healthy and sick—living in the US.

Read more

Virtual health: The time is now

by Ken Abrams, MD, MBA, Managing Director, National Chief Physician Executive, Deloitte Consulting LLP

We are five days away from the start of HIMSS18. One topic that is sure to be a fixture across the show floor and a theme in the educational sessions is that of virtual health. A term that has been in the conversation for some time now is oftentimes used synonymously with digital health, or mobile health,

Read more

Open innovation could lead to a more sustainable health care ecosystem

by Kristin Feeney, Senior Data Scientist, ConvergeHEALTH by Deloitte, Deloitte Consulting LLP

The concept of open innovation extends to every industry, everywhere. Life sciences and health care organizations are no exception, and we are commonly seeing the impact of openness with respect to the explosion of electronic health care data across the ecosystem.

Open innovation can drive the agenda to harness a wealth of extensive network data to help propel innovation in the life sciences industry.

Read more

Predicting and preventing hospital readmission rates

by Doug Beaudoin, Principal, Deloitte Consulting LLP

With the continued shift to value-based care, hospitals are increasingly focused on reducing readmission rates. And preventable readmissions are not just a problem in the US. Globally, 20 percent of patients are readmitted within 30 days of discharge. Researchers in Singapore have developed a web-based tool that predicts a patient’s 15-day readmission rate. By more accurately predicting higher risk patients,

Read more

Real-world evidence: Four shifts ushering in a new era of evidence in life sciences and health care

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

How serious are life sciences companies about real-world evidence (RWE)? Very, according to our new benchmark survey focused solely on the life sciences industry’s investments in RWE. More than half (54 percent) of the organizations who participated in the interviews said they are investing significantly in their RWE programs to increase their capabilities.

Read more